A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

Abstract Background Multiple studies have indicated that patients with high body mass index (BMI) may have favourable survival outcomes following treatment with an immune checkpoint inhibitor (ICI). However, this evidence is limited by several factors, notably the minimal evidence from randomised co...

Full description

Bibliographic Details
Main Authors: Lee X. Li, Mark A. Socinski, Ganessan Kichenadasse, Christos S. Karapetis, Adel Shahnam, Ross A. McKinnon, Andrew Rowland, Ashley M. Hopkins, Michael J. Sorich
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Cancer
Subjects:
Immune checkpoint inhibitor
Chemoimmunotherapy
Body mass index
Non-small-cell lung cancer
Online Access:https://doi.org/10.1186/s12885-024-12132-w

Internet

https://doi.org/10.1186/s12885-024-12132-w

Similar Items